V-SMENP-DC vaccine is made by modifying DC with lentivirus vectors expressing Covid-19 minigene SMENP and immune modulatory genes. CTLs will be activated by LV-DC presenting Covid-19 specific antigens.

Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.

Inactive viral vaccines are created by propagating viruses in cell culture (such as in Vero cells) followed by inactivation using a chemical reagent (such as beta-propiolactone). Upon vaccination, this allows the body to generate a diverse immune response against numerous viral antigens while having no threat of actually being infected because the virus is inactive.

The SARS-CoV-2 rS vaccine is an intramuscularly delivered nanoparticle vaccine. The nanoparticles are created by infecting Sf9 insect cells with baculoviruses viral vectors that express the SARS-CoV-2 spike protein.

The proteins properly fold, undergo a series of programmed modifications, and are ultimately transported to the cell surface. Correctly folded and modified spike proteins are then extracted from the cell surface and purified to maintain their three-dimensional structure and biological activity, ultimately serving as the immunogenic molecule in the vaccine.

The vaccine is also being tested with Matrix M adjuvant, a saponin-based adjuvant that acts in part by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in the local lymph nodes.

Вакцина разработана на основе ДНК аденовируса, в которую встроен ген коронавируса SARS-CoV-2. 

Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses that pose a threat to health and national security, including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika.

Антикоагулянт прямого действия. Применяется для профилактики и терапии тромбоэмболических заболеваний.

Mechanisms may include inhibition of viral enzymes or processes such as viral DNA and RNA polymerase, viral protein glycosylation, virus assembly, new virus particle transport, and virus release. Other mechanisms may also involve ACE2 cellular receptor inhibition, acidification at the surface of the cell membrane inhibiting fusion of the virus, and immunomodulation of cytokine release.

Статус Emergency use authorization (EUA) FDA отозван 15 июня 2020 г.